Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

导出原文传递

翻译打印收藏纠错

作者： Yoshimasa,Shiraishi ^[1] ; Junji,Kishimoto ^[2] ; Kentaro,Tanaka ^[1] ; Shunichi,Sugawara ^[3] ; Haruko,Daga ^[4] ; Katsuya,Hirano ^[5] ; Koichi,Azuma ^[6] ; Osamu,Hataji ^[7] ; Hidetoshi,Hayashi ^[8] ; Motoko,Tachihara ^[9] ; Tetsuya,Mitsudomi ^[10] ; Takashi,Seto ^[11] ; Kazuhiko,Nakagawa ^[8] ; Nobuyuki,Yamamoto ^[12] ; Isamu,Okamoto ^[13]

作者单位： Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. ^[1] Department of Research and Development of Next Generation Medicine, Kyushu University, Fukuoka, Japan. ^[2] Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan. ^[3] Department of Clinical Oncology, Osaka City General Hospital, Osaka, Japan. ^[4] Department of Respiratory Medicine, Hyogo Prefectural Amagasaki General Hospital, Amagasaki, Japan. ^[5] Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan. ^[6] Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan. ^[7] Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan. ^[8] Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. ^[9] Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka, Japan. ^[10] Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. ^[11] Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan. ^[12] Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. Electronic address: okamotoi@kokyu.med.kyushu-u.ac.jp. ^[13]

关键词 Clinical trial Programmed cell death ligand-1 Progression-free survival Superiority Vascular endothelial growth factor